2022
A Comparison of Patient- and Clinician-Reported Acute Toxic Effects During Radiation Therapy for Primary Breast Cancer
Lapen K, King C, Braunstein L, Khan A, Kamrava M, Gillespie E, Cook K. A Comparison of Patient- and Clinician-Reported Acute Toxic Effects During Radiation Therapy for Primary Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 301-309. PMID: 35675851, PMCID: PMC10281649, DOI: 10.1016/j.ijrobp.2022.05.041.Peer-Reviewed Original ResearchConceptsPrimary breast cancerRadiation therapyAcute toxic effectsClinician assessmentBreast cancerPatients warrants further investigationTreatment-related toxic effectsToxic effectsPatient-clinician pairsSymptom burden scoresCommon Terminology CriteriaComparison of patientsStart of treatmentBreast radiation therapyWarrants further investigationTerminology CriteriaAdverse eventsSymptom burdenOutcomes versionPatients' qualityBurden scoreProspective studyUnique patientsLow-severity symptomsPatient response
2021
Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy
Li X, Kitpanit S, Lee A, Mah D, Sine K, Sherman EJ, Dunn LA, Michel LS, Fetten J, Zakeri K, Yu Y, Chen L, Kang JJ, Gelblum DY, McBride SM, Tsai CJ, Riaz N, Lee NY. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. JAMA Network Open 2021, 4: e2113205. PMID: 34143193, PMCID: PMC8214161, DOI: 10.1001/jamanetworkopen.2021.13205.Peer-Reviewed Original ResearchConceptsLocoregional failure-free survivalNonmetastatic nasopharyngeal carcinomaProgression-free survivalIntensity-modulated radiation therapyIntensity-modulated proton therapyCurative-intent radiotherapyIMPT groupIMRT groupAdverse eventsOncologic outcomesOverall survivalSurvival outcomesNasopharyngeal carcinomaMAIN OUTCOMERadiation therapyToxicity profileHigher acute adverse eventsSimilar progression-free survivalTertiary academic cancer centerTreatment-related adverse eventsPropensity score-matched analysisTreatment-related toxic effectsMultivariable logistic regression analysisPoor progression-free survivalChronic grade 3
2013
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer
Tolaney SM, Najita J, Sperinde J, Huang W, Chen WY, Savoie J, Fornier M, Winer EP, Bunnell C, Krop IE. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Annals Of Oncology 2013, 24: 1841-1847. PMID: 23559151, PMCID: PMC3690910, DOI: 10.1093/annonc/mdt121.Peer-Reviewed Original ResearchConceptsMetastatic HER2-positive breast cancerHER2-positive breast cancerCombination of ixabepilonePhase II studyBreast cancerII studyMetastatic diseaseCohort 2Cohort 1Treatment-related toxic effectsClinical benefit rateSubsequent-line therapyTrastuzumab-containing regimensMetastatic breast cancerPrior chemotherapyLine therapyBenefit rateOverall RRDay 1PatientsTrastuzumabIxabepiloneCancerTumor biomarkersCohort
2005
Delayed Neurotoxicity in Primary Central Nervous System Lymphoma
Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, DeAngelis LM, Abrey LE. Delayed Neurotoxicity in Primary Central Nervous System Lymphoma. JAMA Neurology 2005, 62: 1595-1600. PMID: 16216945, DOI: 10.1001/archneur.62.10.1595.Peer-Reviewed Original ResearchConceptsPrimary central nervous lymphomaPathophysiologic mechanismsPrimary central nervous system lymphomaMemorial Sloan-Kettering Cancer CenterTreatment-related toxic effectsCentral nervous system lymphomaDiffuse white matter diseaseAvailable autopsy dataProgressive subcortical dementiaMental status changesNervous system lymphomaDepartment of NeurologyWhite matter damagePotential risk factorsWhite matter diseaseFrontal-subcortical circuitsMicrovascular alterationsNeurologic deteriorationCumulative incidenceClinical courseImproved survivalRetrospective reviewSystem lymphomaClinical findingsSubcortical dementia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply